Perminova

Perminova founder Gregory Feld, MD, Named Among Nation’s Top Cardiac Electrophysiologists

permiadmin — Thu, 19 Jul 2012 21:59:46 +0000

Dr. Gregory Feld, Founder and Chief Medical Officer of Perminova, Inc., and Director of UC San Diego Health System’s Department of Cardiac Electrophysiology, is among the top 1 percent of the nation’s electrophysiologists, according to new rankings of top doctors by U.S. News and World Report.

US News Top Doctors, chosen by peers nationwide, were announced today by the news magazine. Dr. Feld has long been recognized as a leader in the field of electrophysiology, the diagnosis and treatment of abnormal heart rhythms, which is the fastest growing of all cardiovascular disciplines. Dr. Feld developed Perminova EP, a web-based cardiovascular information system customized for electrophysiology.

“I’m honored that my colleagues think highly enough of my work to nominate me among the country’s top electrophysiologists,” Feld said. “Electrophysiology is rapidly growing in importance as we refine techniques to treat abnormal heart rhythms and save lives that may have been lost only a few years ago.”

Dr. Feld originally developed Perminova EP to collect data on electrophysiology (EP) cases for use in research into treatments for abnormal heart rhythms. The product grew into an information system to streamline and improve workflow, scheduling, billing, reporting and sharing patient data among all doctors, nurses and technologists in the EP lab. Because it is web-based, clinicians can access patient data anytime, anywhere and from any browser; automated reporting functions in Perminova EP allow doctors and nurses to complete operative and case reports within minutes of a procedure’s completion without dictation and transcription.

As Dr. Feld originally envisioned, Perminova EP also collects thousands of data points for each electrophysiology procedure and stores them in a scalable, secure private database, where they can be de-identified and used for medical research and clinical trials. Perminova EP is an early example of how big health data can be aggregated for research use to help develop breakthrough treatments.

“Dr. Feld’s vision in creating Perminova is indicative of his national leadership in the field of electrophysiology,” said Craig K. Collins, President & CEO of Perminova. “The recognition is not only for his knowledge and skills as an electrophysiologist, which are immense, but also for his foresight in moving the specialty forward.”

In addition to his position as Director of the Cardiac Electrophysiology Department, Dr. Feld also is Professor of Medicine at UC San Diego School of Medicine. His clinical responsibilities include performing up to eight ablation procedures a week, as well as pacemaker and defibrillator implantation procedures. He currently performs the largest number of ablations for atrial fibrillation in Southern California.
Dr. Feld has pioneered several new treatments for cardiac arrhythmias, including catheter ablation of atrial flutter and AV node modification for atrial fibrillation. His current research includes optimizing techniques for catheter ablation of atrial fibrillation, and development of new energy sources for catheter ablation of atrial fibrillation.

Dr. Feld received his MD degree from Dartmouth Medical School, his residency and fellowship training at UCLA and VA Wadsworth in Los Angeles, and joined the faculty at UC San Diego in 1987. He is a Fellow of the American College of Cardiology, a member of the Editorial Board of the Journal of Interventional Cardiac Electrophysiology and an Associate Editor for the Journal of the American College of Cardiology. Dr. Feld has participated in numerous basic and clinical research studies and his research has been published in the journals Circulation, Heart Rhythm, the Journal of the American College of Cardiology and the American Journal of Cardiology.

About Perminova
La Jolla, Calif.-based Perminova develops and markets web-based software use in cardiovascular surgery. The company is pioneering healthcare’s move from outdated client-server technology to modern, secure cloud computing. Perminova offers customers Software-as-a-Service (SaaS), allowing them to take full advantage of a surgical information system that’s more robust, flexible and cost-effective than currently available. In 2011, the company released Perminova EP, a software module that manages the scheduling, workflow and billing that occur before, during and after cardiac electrophysiological (EP) procedures. Perminova EP enables doctors, nurses and administrators to realize enhanced charge-capture, efficiency and patient safety. The software is currently deployed at leading cardiology centers throughout the United States, including UC San Diego Health System and Mount Sinai Hospital in New York.

Perminova Names Andrew Terry as Vice President of Software Engineering

permiadmin — Thu, 31 May 2012 22:23:28 +0000

Perminova, developer of web-based information systems for the nation’s leading cardiology centers, announced that Andrew (Drew) Terry is the new Vice President of Software Engineering.

Terry, an expert software developer, joins Perminova from Sotera Wireless, Inc., where he was Manager, Embedded Software Engineering. Sotera is a San Diego company that develops wireless body-worn monitoring devices.

“We’re excited about Drew joining our team in this stage of high growth for Perminova,” said Craig K. Collins, President and CEO of Perminova. “We have a number of critical technology initiatives underway, including the advancement of Perminova EP and the integration of medical device data to better serve our clients. Drew will assume a leadership role in the perpetual innovation that has become the hallmark of Perminova.”

At Perminova, Terry will lead an international engineering team to create a host of new, robust features for Perminova EP, the nation’s first web-based information system for cardiac electrophysiology labs. Advancement of Perminova’s information systems will include developing new features to simplify workflow, streamline reporting, improve charge capture and enhance data sharing. Terry also will expand the company’s products to other areas of cardiac care, as well as build out an exciting new mobile health platform that enables cardiologists to manage patients and cases on iPhones, iPads, Droids and other mobile devices. And he will take charge of ongoing progress in the integration of data from cardiac medical devices into Perminova systems.

Prior to serving as Manager, Embedded Software Engineering, at Sotera, Terry was Senior Software Engineer and Lead Software Engineer at the firm. In almost seven years with Sotera, he was instrumental in designing and implementing the company’s vital sign monitoring platform. He also worked on developing and patenting a novel cuff-less blood pressure measurement. He received the company’s annual Founder’s Award for his work in 2010. Most recently, he managed the software team through Sotera’s first FDA 510(k) submission and approval.

Terry holds an MS and BA in computer science from the University of California, San Diego.

Perminova and LifeWatch Announce Device Integration for Cardiac Procedures

permiadmin — Wed, 09 May 2012 18:39:17 +0000

Perminova, developer of web-based information systems for cardiology centers, has launched a strategic alliance with LifeWatch, the leading wireless cardiac monitoring service provider in the United States, to expand interoperability between medical monitoring devices and information technology in cardiac electrophysiology.

Under the arrangement, Perminova EP, the information system designed for electrophysiology, will integrate reports from LifeWatch’s cardiac monitoring and telemetry products directly into Perminova’s cloud-based system. This will provide physicians, nurses, technologists and other staff with a single source for patient information. Future development will also allow clinicians to order LifeWatch cardiac monitoring studies directly from Perminova systems.

The integration process begins with data uploading from a patient prescribed with one of LifeWatch’s suite of advanced ambulatory cardiac telemetry and standard cardiac event monitors to the LifeWatch data center. The LifeWatch data center then pushes the data to Perminova’s database to be matched with patients’ individual files. From there, the data is used by EP lab clinicians and becomes part of the health system’s electronic medical record. This entire process is electronic, greatly reducing the risk of human error.

“The strategic relationship between Perminova and LifeWatch creates important benefits for patients and healthcare systems,” said Craig K. Collins, President and CEO of Perminova. “On a daily basis, it will streamline workflow and improve patient safety in cardiac procedures. In a larger sense, medical device integration between Perminova and LifeWatch creates true interoperability, one of the primary objectives in the advancement of health information technology today.”

Said Dr. Yacov Geva, Chairman and CEO of LifeWatch AG: “Integration between medical devices and information systems is a critical next step in utilizing technology to improve patient health and safety. Medical device integration may also help relieve doctors, nurses and technologists of the burden of creating hard copy documentation, allowing them to spend more time on direct patient care.”

Perminova develops web-based cardiac information systems that manage scheduling, workflow, documentation and billing processes before, during and after cardiac procedures. Perminova’s system architecture also supports integration of medical devices and customization of robust data for research. Perminova’s web-based products are pioneering healthcare’s move from outdated client-server technology to modern-and-secure cloud computing.

LifeWatch is the nation’s leading ambulatory health monitoring services company, offering a comprehensive platform of innovative patient technologies and services that help physicians detect and analyze symptoms before they become major health problems. LifeWatch enables physicians to establish stronger connections with at-risk patients and provide better guidance to patients.

About LifeWatch AG
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Mount Sinai Medical Center deploys Perminova EP

permiadmin — Tue, 24 Apr 2012 17:50:57 +0000

One of nation’s top heart hospitals rolls out web-based cardiac information system.

LA JOLLA, CA – Perminova, developer of a new breed of web-based information systems for the nation’s leading cardiology centers, announced that Mount Sinai Medical Center in New York, one of the nation’s leading heart hospitals, has installed Perminova EP at the Leona M. and Harry B. Helmsley Charitable Trust Center for Cardiac Electrophysiology.

Perminova EP is a web-based cardiovascular information system that manages scheduling, workflow, documentation and billing processes before, during and after cardiac electrophysiology (EP) procedures. Perminova’s web-based products are pioneering healthcare’s move from outdated client-server technology to modern-and-secure cloud computing.

At Mount Sinai, Perminova EP allows clinicians to quickly complete operative and case reports within minutes after a procedure. Reports can be electronically signed and immediately uploaded to the hospital EMR and sent to the billing department. During procedures, a full list of codes for devices, medications and equipment are captured electronically for efficient and timely reimbursement. Documentation and reports created by Perminova EP are highly searchable and can be accessed and completed anytime, anywhere and on any web browser.

“Perminova gives our EP lab the flexibility to access procedure records securely from any location. That means doctors and nurses don’t have to come in on weekends or late at night to catch up on paperwork, or get frustrated when the server is down and they can’t do any documentation,” said Vivek Y. Reddy, MD, Professor of Cardiology and Director of the Cardiac Arrhythmia Service at Mount Sinai Heart. “Improvements in documentation with Perminova EP may ultimately result in improved patient care and safety.”

Like other cardiac labs, Mount Sinai’s busy EP lab previously used email among dozens of people to coordinate patient and staff schedules and link with the billing department. Perminova simplifies and streamlines the daily process of managing an EP lab. Perminova’s features allow staff to proactively manage cases several days in advance, preventing case delays by ensuring each patient has necessary insurance authorization and pre-operative tests.

“Cardiologists have said that they spend more time on the paperwork than they do on the pacemaker,” said Ken Miceli, Senior Director of Information Technology at Mount Sinai’s Cardiovascular Institute and Heart Hospital. “That’s going to change with Perminova EP. We see the entire documentation process becoming easier yet more comprehensive, and this will provide both administrative and clinical improvements for the EP lab.”

In addition to workflow and scheduling, Perminova EP also dramatically improves billing by eliminating lost charge sheets and reducing reimbursement denials, while reports from each procedure are automatically available to Mount Sinai’s billing department. Perminova EP also helps the EP lab go paperless, a goal for the entire Mount Sinai Medical Center.

Perminova products are browser-based and cloud-based, deploying and upgrading easily via the web with rapid configuration, integration and customization. Deploying Perminova EP is relatively inexpensive compared to enterprise software and does not require expensive new hardware. Perminova products can be seamlessly integrated into any hospital’s electronic medical records system. Perminova’s architecture allows integration of medical devices and customization of robust data for medical research and clinical trials.

“The deployment of Perminova EP at Mount Sinai Medical Center makes one of the nation’s top EP labs even better by simplifying operations, sharing data and enabling research,” said Craig K. Collins, President and CEO of Perminova Inc. “Mount Sinai’s physicians, nurses and technologists will spend more time on direct patient care while the lab’s charge capture increases. State-of-the-art electrophysiology truly moves into the 21st century with Perminova EP.”

About Mount Sinai Medical Center
The Mount Sinai Medical Center, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2011, US News and World Report ranked The Mount Sinai Medical Center 16th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place. Mount Sinai Medical Center ranks among the nation’s best hospitals for cardiology and heart surgery in the 2011-2012 “Best Hospitals” issue of US News & World Report.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Keith Wahl, MD, Joins Perminova Board of Advisors

permiadmin — Wed, 29 Feb 2012 00:32:11 +0000

Perminova, developer of web-based software for use in the nation’s leading cardiology centers, announced today that Keith Wahl, MD, has joined the Perminova Board of Advisors.

As a member of the Perminova Board of Advisors, Dr. Wahl contributes nearly 40 years as a practicing surgeon and significant experience as consultant and mentor to early- and middle-stage businesses in health-related fields.

“Keith Wahl brings to Perminova experience in both surgery and management of startup companies,” said Craig Collins, President and CEO of Perminova, Inc. “His knowledge and energy will be important for the company as we enter a high-growth period in products, services and clients.”

Dr. Wahl is founder of A-K Technology Consultants, a company that evaluates start-up and early-stage companies for business development and funding opportunities. He has been a Board of Advisors member for SinusPharma, a company that specializes in sinus care therapies. Dr. Wahl was COO of VR Neurotech LLC, a start-up company that produced a life-saving device for fatigued drivers and equipment operators. And he was founder of Advanced Data Concepts Computer Systems, an early software developer for ambulatory surgery center billing. Dr. Wahl is a medical consultant to the State of California Department of Social Services and the Medical Board of California.

Dr. Wahl has been practicing medicine since 1972. He is a Fellow at the American College of Surgeons, American Academy of Facial Plastic and Reconstructive Surgery, American Society of Head and Neck Surgeons, American Academy of Cosmetic Surgery and American Academy of Liposuction Surgery. Dr. Wahl was Chief of Otolaryngology/Head and Neck Surgery at Sharp Memorial Hospital in San Diego, Chief of Otolaryngology at Scripps Memorial Hospital in San Diego, and Chief of Surgery and Chief of Staff at Pioneers Memorial Hospital in Brawley. Dr. Wahl was an assistant clinical professor at UC San Diego School of Medicine, and taught at many other institutions as well.

He graduated from UCLA with a BS in pre-med and earned his MD at UC Irvine. His residencies in general surgery and otolaryngology/head and neck surgery were completed at UCLA and Stanford University.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Perminova names medical technology entrepreneur Michael Perry to Board of Advisors

permiadmin — Thu, 16 Feb 2012 21:42:06 +0000

Perminova, developer of web-based software for the nation’s leading cardiology centers, announced that Michael K. Perry has joined the Perminova Board of Advisors.

With over 25 years of leadership experience in the medical technology industry, Perry is currently Chief Executive Officer and Director of CRISI Medical Systems, a San Diego-based medical technology company that develops innovative medication management products designed to make the delivery of intravenous drugs safer, more accurate and more cost-effective.

“Mike is a very innovative entrepreneur in medical technology industries, with particular insight in the field of cardiology,” said Perminova President and CEO Craig Collins. “His experiences in leading companies from start-up to success will provide invaluable help to Perminova as a high-growth technology company.”

From 1998 to 2009, Perry was CEO and Director of CardioDynamics, the innovator of a new measurement technology to noninvasively access a patient’s cardiac performance. Perry successfully built the public company from zero revenue to a $41 million profitable business before it was sold to SonoSite, Inc. In 2003, Perry was named San Diego Entrepreneur of the Year for Medical Products and Technology.

Prior to CardioDynamics, he was Vice President of Operations and Vice President for Research and Development at Pyxis Corporation. Pyxis Corporation was a pioneer of healthcare automation and information management services, in addition to pharmacy management services to hospitals and outpatient facilities. Perry was part of the executive team that successfully acquired and integrated three businesses into Pyxis, and in 1996 sold the company to Cardinal Health, Inc.

Before joining Pyxis, Perry served in several management assignments with Hewlett-Packard’s Medical Products Group in manufacturing and finance. Additionally, he was Director of Quality for a division of Hewlett-Packard’s DeskJet Printer Group.

Perry holds an MBA from Harvard University and a BS degree in Mechanical Engineering from General Motors Institute. Perry serves as an Executive Committee member of the Advisory Board of the UC San Diego Cardiovascular Center. He and his wife, Karilyn, are among the founding families of Pacific Ridge School, an independent school in Carlsbad, California.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Cleland Landolt, MD, brings extensive corporate and medical experience to Perminova Board of Advisors

permiadmin — Wed, 08 Feb 2012 21:41:03 +0000

Perminova, developer of web-based software for the nation’s leading cardiology centers, announced today that Cleland Landolt MD, FACS, FACC, FACP, has joined the Perminova Board of Advisors.

Dr. Landolt brings extensive experience to the Perminova Board of Advisors as a life sciences industry executive and consultant following a successful clinical career as a cardiothoracic and vascular surgeon. In various corporate roles, he has run strategic and business development groups, and served as chief medical officer and chief operating officer. He currently provides a wide range of medical and strategic consulting services to start-up and established medical device and life sciences companies.

“A successful thoracic surgeon with deep experience in the life sciences industry is a tremendous asset to Perminova as an advisor,” said Craig Collins, President and CEO of Perminova. “Dr. Landolt provides a remarkable blend of expertise in medicine and business that Perminova needs at this early stage of its development.”

Dr. Landolt served as Chief Medical Officer and Chief Operating Officer for Novellus Research Sites, a multi-site clinical research company, where he functioned as Principal Investigator or Sub-Investigator on every clinical trial. Previously, he was Chief Medical Officer and Vice President of Corporate Development for Berkeley HeartLab, Inc., part of the Celera Group, a laboratory diagnostics business. Dr. Landolt, who had primary strategic responsibility for developing emerging technologies and new ventures, also initiated strategic planning for Berkeley’s $195 million acquisition by Celera. Prior to that, he served as Vice President for Business Development of Collateral Therapeutics, Inc., an early-stage biotechnology company focused on clinical development of cardiovascular gene therapy.

Prior to transitioning to industry in 2001, Dr. Landolt had successful cardiac surgical practices on the East and West Coasts, preceded by teaching appointments at Harvard University, University of California San Francisco, and Emory University. Dr. Landolt received his undergraduate degree from Harvard College, his M.D. from Cornell University Medical College, and completed a post-doctoral research fellowship at the Cardiovascular Research Institute, San Francisco.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Former New Jersey Health Commissioner Dr. Poonam Alaigh named Perminova Advisor

permiadmin — Tue, 17 Jan 2012 21:53:01 +0000

Perminova, developer of web-based software for the nation’s leading cardiology centers, announced that Poonam Alaigh, MD, has joined the Perminova Board of Advisors.

A board-certified internist with a vascular medicine specialty, Dr. Alaigh also has a comprehensive knowledge of health policy, healthcare reform, cost-effective care and quality outcomes, along with expertise in organizational and corporate management. She was Commissioner of Health and Senior Services for the State of New Jersey, where she led an executive-level state agency with a $3.8 billion budget and 1,700 employees and answered directly to the Governor. Her key responsibilities included state and national healthcare policy, public health, senior care and quality and regulatory oversight of healthcare institutions in New Jersey.

“Perminova is fortunate to have on its Board of Advisors an MD with Dr. Alaigh’s tremendous expertise in healthcare policy, along with organizational and corporate management,” said Craig K. Collins, Perminova President and CEO. “In this fast-changing era for healthcare, her knowledge will be extremely beneficial to our high-growth health technology company.”
Previously, she was Executive Medical Director of Horizon Blue Cross Blue Shield of New Jersey, National Medical Director of GlaxoSmithKline Pharmaceuticals, Medical Director of Vytra Health Plans of New York, and Associate Medical Director of the Long Island Medical Care Group.

Her clinical practice was at the Veterans Administration Hospital in Lyons, NJ. Dr. Alaigh also is an Assistant Professor in the Department of Family Practice at UMDNJ-Robert Wood Johnson Medical School. She has been very active in the American Heart Association, including as a Board Member of the Founders Affiliate, President of the Board for New Jersey and Board Member for the Tristate Region.

Dr. Alaigh received her medical degree from Lady Hardinge Medical College at Delhi University in India and later an MS in Health Care Policy and Management at SUNY at Stony Brook in New York.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Perminova Names Business, Science and Academic Leader Gail Naughton to Board of Advisors

permiadmin — Wed, 04 Jan 2012 17:01:01 +0000

Perminova, developer of web-based software for the nation’s leading cardiology centers, announced that Gail Naughton, Ph.D., a leader in business, finance, biomedicine and academia, has joined the Perminova Board of Advisors.

Naughton is currently CEO and Chairman of Histogen, Inc., a regenerative medicine company she founded in 2007 to develop novel treatments for conditions ranging from hair loss to cancer. She also serves as a Director for C.R. Bard, Inc., a global company whose lectrophysiology Division develops diagnostic devices for treating cardiac arrhythmias. Previously, Naughton was Dean of the College of Business Administration at San Diego State University, a position she held for nine years. She was the first female biotechnology entrepreneur to lead a major U.S. business school. At SDSU, Naughton was part of an administration that dramatically boosted the school’s academic performance and reputation.

“An Advisor the caliber of Gail Naughton brings tremendous benefit to Perminova,” said Craig K. Collins, President & CEO of Perminova. “Her breadth of knowledge and experience in medical research, industry and academia is remarkable. She will provide invaluable expertise as Perminova expands operations and launches new products in the health technology market.”

Prior to joining San Diego State, Naughton was a respected scientist and executive, with an accomplished background in the field of tissue engineering. She co-founded Advanced Tissue Sciences in 1986, serving as Principal Scientist before rising to Executive VP, Chief Scientific Officer, and then President and Chief Operating Officer. At Advanced Tissue Sciences, she was Co-Inventor of the company’s core technology, and oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue-engineered products. Naughton held professorships at City University of New York, Hunter College and York College. She also was Assistant Professor of Research at New York University Medical Center.

Naughton holds over 95 U.S. and foreign patents and is extensively published in the field of tissue engineering. In 2000, she received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Naughton is co-author of “Patents in the Knowledge-Based Economy,” published in 2003 by the National Research Council of the National Academic Press, and she served on the National Academy Committee for Patent Reform.

She is an Advisory Board member of the Parker H. Petit Institute for Bioengineering and Bioscience at Georgia Institute of Technology, and a member of the Board of Directors for the Ackerman Foundation. Naughton received the ARCS Foundation’s National Scientist of the Year award in 1998 and the Lindbergh-Carrel Prize in 2002, and was named Woman of the Year by San Diego Magazine in 2006.

Naughton earned a BS from St. Francis College, Brooklyn, New York, and both an MS in Histology and a Ph.D. in Hematology from New York University Medical Center. She also holds an MBA in Executive Management from the Anderson School at UCLA.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com

Perminova names Technology Industry Executive Kevin Hell as Board Member

permiadmin — Mon, 19 Dec 2011 18:50:07 +0000

Perminova, developer of web-based software for the nation’s leading cardiology centers, named Kevin Hell to the Perminova Board of Directors.

A technology industry leader with expertise in managing high-growth operations, launching innovative products and helping technology start-ups attract capital, Hell is Chairman of EvoNexus, a highly successful business incubator for high-tech startups. EvoNexus is part of CommNexus, a non-profit technology industry association in San Diego. Hell is a member of the Board of Directors for CommNexus.

“Kevin brings to Perminova invaluable experience in technology operations, corporate leadership and product development,” said Craig Collins, Perminova’s President & CEO. “The company will benefit greatly from having access to Kevin’s expertise. We look forward to his guidance as we expand operations and launch new products into the healthcare market.”

Hell also serves as Chairman of the Board of Directors for Pixon Imaging and Micropower Technologies. Hell was formerly CEO and Board Member of DivX, Inc. During his eight-year tenure there, he drove the company through an IPO and transformed it into a leader in the rapidly emerging digital video market, connecting high-quality Internet content with consumer electronics.

Before joining DivX, Hell served as Senior Vice President of Product Management for Palm’s Solutions Group, where he managed the Palm-branded products and wireless services division worldwide. Prior to Palm, Hell was Vice President of the Connected Home for Gateway and was responsible for pioneering innovative digital home products beyond the PC. He received an MBA in finance and management from The Wharton School of the University of Pennsylvania, and an MS and BS in engineering from Stanford University.

Contact: Eileen Lane, VP Marketing, 858-255-0011, eileen.lane@perminova.com